Cantor Fitzgerald Lowers Earnings Estimates for CG Oncology

CG Oncology, Inc. (NASDAQ:CGON) – Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for CG Oncology in a note issued to investors on Monday, August 11th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings of ($2.19) per share for the year, down from their prior forecast of ($1.83). Cantor Fitzgerald has a “Overweight” rating and a $75.00 price objective on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. Cantor Fitzgerald also issued estimates for CG Oncology’s FY2026 earnings at ($3.80) EPS.

CGON has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a research report on Monday, April 28th. Scotiabank began coverage on CG Oncology in a research report on Wednesday, April 16th. They set a “sector perform” rating and a $23.00 price objective on the stock. The Goldman Sachs Group raised CG Oncology to a “strong-buy” rating and set a $40.00 price objective on the stock in a research report on Thursday, July 10th. Royal Bank Of Canada cut their price objective on CG Oncology from $68.00 to $53.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 16th. Finally, JPMorgan Chase & Co. began coverage on CG Oncology in a research report on Friday, May 2nd. They set an “overweight” rating and a $41.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $55.30.

CG Oncology Trading Up 6.2%

CG Oncology stock opened at $26.49 on Wednesday. CG Oncology has a twelve month low of $14.80 and a twelve month high of $40.47. The stock’s fifty day simple moving average is $26.20 and its 200-day simple moving average is $25.57. The firm has a market capitalization of $2.02 billion, a P/E ratio of -14.97 and a beta of 0.87.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative return on equity of 19.37% and a negative net margin of 15,945.17%.

Insider Activity at CG Oncology

In related news, Director Leonard E. Post sold 2,000 shares of the business’s stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $28.00, for a total transaction of $56,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On CG Oncology

A number of institutional investors and hedge funds have recently modified their holdings of CGON. JPMorgan Chase & Co. boosted its stake in CG Oncology by 443.5% in the fourth quarter. JPMorgan Chase & Co. now owns 168,866 shares of the company’s stock valued at $4,843,000 after acquiring an additional 137,795 shares in the last quarter. Geode Capital Management LLC boosted its stake in CG Oncology by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 1,156,670 shares of the company’s stock valued at $33,181,000 after acquiring an additional 78,143 shares in the last quarter. Wells Fargo & Company MN boosted its stake in CG Oncology by 45.3% in the fourth quarter. Wells Fargo & Company MN now owns 28,234 shares of the company’s stock valued at $810,000 after acquiring an additional 8,803 shares in the last quarter. Federated Hermes Inc. acquired a new position in CG Oncology in the fourth quarter valued at $172,000. Finally, Invesco Ltd. boosted its stake in CG Oncology by 75.7% in the fourth quarter. Invesco Ltd. now owns 27,069 shares of the company’s stock valued at $776,000 after acquiring an additional 11,662 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.